| Median age, y (range) | 65, (35-78) |
| Sex | |
| Female | 9 |
| Male | 18 |
| Race | |
| White | 19 |
| Black | 6 |
| Asian | 2 |
| Ethnicity | |
| Hispanic | 7 |
| Non-Hispanic | 20 |
| ECOG PS | |
| 0 | 5 |
| 1 | 13 |
| 2 | 8 |
| 3 | 1 |
| PTCL subtype | |
| AITL | 19 |
| ATLL | 2 |
| TFH-PTCL | 3 |
| PTCL-NOS | 1 |
| Composite (TFH-PTCL + DLBCL and ALK- ALCL + FL) | 2 |
| Stage at romidepsin azacitidine start | |
| I-II | 8 |
| III-IV | 19 |
| Median number of previous therapies (range) | 1 (0-5) |
| Treatment-naive | 3 |
| Previous therapies | |
| Anthracycline-based | 20 |
| Platinum-based | 7 |
| Pralatrexate | 3 |
| Anti-CD20 | 4 |
| Brentuximab | 8 |
| Other therapy | 7 |
| ASCT | 7 |
| Median age, y (range) | 65, (35-78) |
| Sex | |
| Female | 9 |
| Male | 18 |
| Race | |
| White | 19 |
| Black | 6 |
| Asian | 2 |
| Ethnicity | |
| Hispanic | 7 |
| Non-Hispanic | 20 |
| ECOG PS | |
| 0 | 5 |
| 1 | 13 |
| 2 | 8 |
| 3 | 1 |
| PTCL subtype | |
| AITL | 19 |
| ATLL | 2 |
| TFH-PTCL | 3 |
| PTCL-NOS | 1 |
| Composite (TFH-PTCL + DLBCL and ALK- ALCL + FL) | 2 |
| Stage at romidepsin azacitidine start | |
| I-II | 8 |
| III-IV | 19 |
| Median number of previous therapies (range) | 1 (0-5) |
| Treatment-naive | 3 |
| Previous therapies | |
| Anthracycline-based | 20 |
| Platinum-based | 7 |
| Pralatrexate | 3 |
| Anti-CD20 | 4 |
| Brentuximab | 8 |
| Other therapy | 7 |
| ASCT | 7 |
AITL, angioimmunoblastic lymphoma; ALK- ALCL, anaplastic lymphoma kinase negative anaplastic large cell lymphoma; ASCT, autologous stem cell transplant; ATLL, adult T-cell leukemia/lymphoma; DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; NOS, not otherwise specified.